| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | VRK3 |
| Uniprot No | Q8IV63 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-474aa |
| 氨基酸序列 | MISFCPDCGKSIQAAFKFCPYCGNSLPVEEHVGSQTFVNPHVSSFQGSKR GLNSSFETSPKKVKWSSTVTSPRLSLFSDGDSSESEDTLSSSERSKGSGS RPPTPKSSPQKTRKSPQVTRGSPQKTSCSPQKTRQSPQTLKRSRVTTSLE ALPTGTVLTDKSGRQWKLKSFQTRDNQGILYEAAPTSTLTCDSGPQKQKF SLKLDAKDGRLFNEQNFFQRAAKPLQVNKWKKLYSTPLLAIPTCMGFGVH QDKYRFLVLPSLGRSLQSALDVSPKHVLSERSVLQVACRLLDALEFLHEN EYVHGNVTAENIFVDPEDQSQVTLAGYGFAFRYCPSGKHVAYVEGSRSPH EGDLEFISMDLHKGCGPSRRSDLQSLGYCMLKWLYGFLPWTNCLPNTEDI MKQKQKFVDKPGPFVGPCGHWIRPSETLQKYLKVVMALTYEEKPPYAMLR NNLEALLQDLRVSPYDPIGLPMVP |
| 预测分子量 | 80 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于VRK3重组蛋白的3篇参考文献及其摘要概括：
1. **文献名称**: "Cloning, expression, and functional characterization of human VRK3 kinase"
**作者**: Smith A, et al.
**摘要**: 该研究成功克隆并表达了人源VRK3重组蛋白，通过大肠杆菌表达系统纯化获得高纯度蛋白。实验证实重组VRK3具有磷酸化特定底物的激酶活性，并发现其活性受细胞氧化应激条件调控。
2. **文献名称**: "Structural insights into the inactive state of VRK3 through recombinant protein crystallography"
**作者**: Lee J, et al.
**摘要**: 研究利用昆虫细胞系统表达并纯化VRK3重组蛋白，通过X射线晶体学解析其三维结构。结果表明，VRK3的非活性构象由其N端结构域的自抑制机制维持，为靶向VRK3的药物设计提供了结构基础。
3. **文献名称**: "VRK3 regulates cell cycle exit by modulating p53 signaling in vitro"
**作者**: Chen L, et al.
**摘要**: 通过哺乳动物细胞表达系统制备重组VRK3蛋白，发现其通过去磷酸化p53蛋白负向调控细胞周期进程。体外实验表明，重组VRK3直接与p53相互作用，影响下游靶基因表达。
4. **文献名称**: "Development of a VRK3 kinase activity assay using recombinant protein and high-throughput screening"
**作者**: Müller R, et al.
**摘要**: 研究建立了基于重组VRK3蛋白的体外激酶活性检测体系，优化了荧光底物检测方法，并应用于高通量药物筛选，成功鉴定出多个小分子抑制剂，为VRK3相关疾病治疗提供潜在工具。
注：以上文献信息为示例性内容，实际研究中需根据具体数据库检索真实文献。建议通过PubMed或Web of Science以“VRK3 recombinant protein”为关键词进一步筛选。
VRK3 (Vaccinia-Related Kinase 3) is a serine/threonine kinase belonging to the VRK protein family, which shares structural homology with vaccinia virus B1R kinase. Unlike its paralogs VRK1 and VRK2. VRK3 exhibits unique regulatory features, including a lack of catalytic activity toward typical kinase substrates due to critical amino acid substitutions in its ATP-binding pocket. This catalytically inactive pseudokinase status suggests non-enzymatic roles in cellular signaling.
Originally identified in 2003. VRK3 is implicated in stress response pathways and cell cycle regulation. It interacts with protein phosphatase 1 (PP1) to modulate MAPK signaling, particularly influencing ERK1/2 dephosphorylation. Emerging studies link VRK3 to neurological functions, cancer progression, and DNA damage response, though its exact mechanisms remain incompletely understood.
Recombinant VRK3 proteins are typically produced in bacterial (e.g., E. coli) or mammalian expression systems for structural and functional studies. These purified proteins enable investigation of VRK3's scaffold functions, including its ability to form heterocomplexes with signaling molecules. Research applications range from crystallography to drug discovery efforts targeting pseudokinase-mediated pathways. Current challenges include elucidating VRK3's physiological substrates and clarifying its dual roles in neurodevelopment and tumor suppression/progression. As an atypical kinase family member, VRK3 continues to attract interest for its potential as a therapeutic target and regulator of cellular stress adaptation.
×
